Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
- AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase ...
Read more